Roivant Sciences Eyes Imminent Brepocitinib Launch as Pipeline Advances
The UK biotech firm reports progress across its clinical programs while preparing for a potential dermatomyositis drug launch by end of September.
A Quiet Quarter Before the Storm
Roivant Sciences Ltd. (ROIV) reported what CEO Matthew Gline characterized as "a quiet quarter" for the three months ended June 30, 2026, while setting expectations for what he described as "the next 6 to 12 months" being "in many ways, easier than the prior 6 to 12 months" (earnings call, 2026-08-06).
The company's primary focus remains the anticipated launch of brepocitinib for dermatomyositis, expected "by the end of September" following priority review from the FDA (earnings call, 2026-08-06). Gline emphasized a measured approach to commercialization, stating that "slow and steady is what we're looking to build" as the company prepares for multiple potential indications beyond dermatomyositis (earnings call, 2026-08-06).
Pipeline Expansion in Sarcoidosis
A key development during the quarter was the enrollment of patients in a Phase III study evaluating brepocitinib for cutaneous sarcoidosis, "a little bit ahead of schedule," according to Gline (earnings call, 2026-08-06). The 140-patient study will assess the drug over 16 weeks across approximately 70 sites, with patients randomized 3:2 to receive either 45 milligrams of brepocitinib or placebo.
The decision to advance into Phase III follows Phase II data showing "a greater than 20-point benefit" on the CSAMI scale compared to "roughly nothing on placebo" (earnings call, 2026-08-06). Roivant estimates the addressable U.S. market at "about 40,000 patients" with "high unmet need" (earnings call, 2026-08-06). Top-line data from the Phase III study is expected in 2028.
Near-Term Data Catalysts
The company outlined several anticipated data readouts for the second half of 2026, including top-line results from brepocitinib's Phase II study in non-infectious uveitis (NIU), "an indication that could easily be as large as dermatomyositis" (earnings call, 2026-08-06). Additional data is expected from Merck's bartastinib Phase II study in pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Roivant also expects to provide updates on Immunovant's DTRA program, including results from "the second part of the study" and details on FDA discussions (earnings call, 2026-08-06).
Enrollment continues in the lichen planopilaris (LPP) study announced earlier in 2026, which Gline said is progressing "extremely well" with "a lot of enthusiasm from physicians and patients" (earnings call, 2026-08-06).
Financial Position and Capital Allocation
For the quarter, Roivant reported R&D expenses of "about $200 million" and non-GAAP adjusted G&A of "just under $100 million" (earnings call, 2026-08-06). The company held cash of "just under $4 billion" as of quarter-end, before receiving $772 million from the Moderna settlement (earnings call, 2026-08-06).
Roivant accelerated share repurchases following the Moderna settlement announcement, buying back "about $200 million" worth of shares during the quarter at an average price "in the high 20s" (earnings call, 2026-08-06). This compared favorably to earlier repurchases executed "at around $10 a share" (earnings call, 2026-08-06).
The company also filed international patent infringement lawsuits against Pfizer-BioNTech in Canada and the Unified Patent Court in July 2026, while awaiting a Federal Circuit ruling on the 4098 patent that could yield an additional "$1.3 billion" (earnings call, 2026-08-06).
This article was generated by MarginX from the earnings call on 2026-08-06. It is not investment advice.